Peptides DB
Research-centric peptide and protocol reference hub

Cerebrolysin record · updated 21h ago

Neuro & moodHealing & recoveryGrade A · human clinicalResearch use only
All 18 studiesJump to the evidenceCompare
What is Cerebrolysin used for?

Cerebrolysin is a porcine brain-derived peptide preparation studied for stroke recovery, dementia, and TBI, with proposed neurotrophic and neuroprotective effects on the central nervous system.

How it works: Neurotrophic and neuroprotective effects

Primarily researched for · Neuro & moodRoute · Intravenous or intramuscular injection

Development stage

where Cerebrolysin sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 75 registered trials. It describes the research record, not a recommendation.

Identity
NameCerebrolysin
Chain length—
Molecular weight—
Formula—
Structure type—
ClassNeuro
Research levelWell Studied
Discovered byCurated master list · 2026
Pharmacology
MechanismNeurotrophic and neuroprotective effects
RouteIntravenous or intramuscular injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.70
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 20, 2026. How this works →
Research stats
Total studies18
Human / animal / cellular7 / 1 / 5
Highest trial phasePhase 4
Years covered2024–2026
Latest study6d ago
Publication history
20242026
Research funding
3 NIH projects · $503k awarded · through FY2017
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports83
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

18 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Near-IR laser-induced and spontaneous conformational transformations in monomers of 9-methylhypoxanthine.
FindingNot reported in abstract.
In vitro2026Full text read0.70
24-Epibrassinolide enhances aluminum tolerance in tobacco through Ca²⁺-dependent signaling, antioxidant regulation, and metal homeostasis.
FindingNot reported in abstract.
In vitro2026Full text read0.80
Unleashing the power of DNA-encoded libraries for challenging targets in drug discovery.
TakeawayDEL technology is evolving into a powerful tool for drug discovery, particularly for challenging targets, with AI integration being a key advancement.
review2026Full text read0.80
Influence of sound vibrations on plant holobionts: physiological pathways linking root function and rhizospheric microbial interactions.
TakeawaySound vibrations might influence plant and microbial interactions through mechanotransduction, but empirical validation is needed to confirm this model.
review2026Full text read0.80
Ubiquitin-specific protease 11 facilitates the activation and proliferation of renal interstitial fibroblasts through epidermal growth factor receptor signaling pathways.
Finding70-90% reduction in α-SMA and collagen I expressions with USP11 depletion.
In vitro2026Full text read0.80
AI-assisted case-based learning and flipped classroom to improve clinical decision-making: a randomized controlled trial in reproductive medicine.
FindingAI-assisted CBL+FC group achieved significantly higher theoretical test scores than control.
Human2026Full text read0.80
Systems engineering of <i>Escherichia coli</i> for high-level hydroxytyrosol production.
FindingHT titer of 9.25 g/L achieved in E. coli.
In vitro2026Full text read0.80
Performance and behavior of dairy calves fed corn silage in the diet during the pre- and post-weaning periods.
FindingDMI, feed conversion, ADG, and protein intake did not differ between treatments (P > 0.05).
Animal2026Full text read0.80
Salinity signaling networks in wheat: crosstalk among Ca<sup>2</sup>⁺, ROS, phytohormones, and metabolic signals in salt adaptation.
TakeawayUnderstanding wheat's salinity adaptation as a network of interconnected signals could inform breeding and agronomic strategies to enhance performance in saline environments.
review2026Full text read0.80
Cerebrolysin, Hemorrhagic Transformation, and Anticoagulation Timing after Reperfusion Therapy in Stroke: Secondary Analysis of the CEREHETIS Trial
FindingHazard ratio for symptomatic HT in HTI > 0 cohort: 0.245 (95% CI 0.072–0.837; p = 0.020)
Human2024Full text read0.80
Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients With Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a three-month follow-up of a Prospective, Open Label, Single-Center Study
Finding68% mRS 0–2 at 90 days vs 44% in controls, p=0.016, OR 2.7, 95%CI 1.2 - 6.1; NNT: 4.2
Human2025Full text read0.80
A Real-World Data Analysis of Adverse Drug Reactions Associated with Neuroprotective Agents: Insights from WHO-VigiAccess
Finding132,476 ADR reports for Cerebrolysin.
review2025Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Cerebrolysin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Cerebrolysin is discussed should be drawn from it.